Zacks Investment Research Weighs in on SQZ Biotechnologies’ Q2 2022 Earnings (NYSE:SQZ)

SQZ Biotechnologies (NYSE:SQZGet Rating) – Zacks Investment Research issued their Q2 2022 earnings per share (EPS) estimates for SQZ Biotechnologies in a report issued on Wednesday, May 11th. Zacks Investment Research analyst J. Vandermosten expects that the company will post earnings of ($0.71) per share for the quarter. Zacks Investment Research also issued estimates for SQZ Biotechnologies’ Q4 2022 earnings at ($0.69) EPS, FY2022 earnings at ($2.86) EPS, FY2023 earnings at ($2.19) EPS and FY2024 earnings at ($2.03) EPS.

SQZ Biotechnologies (NYSE:SQZGet Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative return on equity of 54.44% and a negative net margin of 303.43%.

Shares of NYSE SQZ opened at $3.32 on Monday. The firm has a market cap of $93.45 million, a PE ratio of -1.26 and a beta of 3.73. SQZ Biotechnologies has a 12-month low of $2.73 and a 12-month high of $16.17. The company’s fifty day simple moving average is $4.19 and its 200 day simple moving average is $7.66.

Several institutional investors have recently added to or reduced their stakes in SQZ. Citigroup Inc. lifted its stake in shares of SQZ Biotechnologies by 139.6% in the third quarter. Citigroup Inc. now owns 2,595 shares of the company’s stock valued at $37,000 after buying an additional 1,512 shares in the last quarter. Royal Bank of Canada lifted its position in shares of SQZ Biotechnologies by 96.2% during the third quarter. Royal Bank of Canada now owns 3,059 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares in the last quarter. Bangor Savings Bank bought a new position in shares of SQZ Biotechnologies during the fourth quarter valued at about $99,000. UBS Group AG lifted its position in shares of SQZ Biotechnologies by 85.8% during the third quarter. UBS Group AG now owns 7,000 shares of the company’s stock valued at $101,000 after purchasing an additional 3,233 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of SQZ Biotechnologies during the third quarter valued at about $104,000. 66.56% of the stock is currently owned by hedge funds and other institutional investors.

About SQZ Biotechnologies (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Read More

Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.